Literature DB >> 30044299

Pharmacological Characters of Oliceridine, a μ-Opioid Receptor G-Protein-Biased Ligand in Mice.

De-Yong Liang1,2, Wen-Wu Li2, Chinwe Nwaneshiudu2, Karen-Amanda Irvine1,2, J David Clark1,2.   

Abstract

BACKGROUND: A major advancement in the field of analgesic pharmacology has been the development of G-protein-biased opioid agonists that display less respiratory depression than conventional drugs. It is uncertain, however, whether these new drugs cause less tolerance, hyperalgesia, and other maladaptations when administered repeatedly.
METHODS: The archetypical µ-opioid receptor agonist morphine and, separately, the G-protein-biased µ-opioid receptor agonist oliceridine were administered to mice. These drugs were used in models of acute analgesia, analgesic tolerance, opioid-induced hyperalgesia, reward, and physical dependence. In addition, morphine and oliceridine were administered for 7 days after tibia fracture and pinning; mechanical allodynia and gait were followed for 3 weeks. Finally, the expression of toll-like receptor-4 and nacht domain-, leucine-rich repeat-, and pyrin domain-containing protein 3 (NALP3) and interleukin-1β mRNA were quantified in spinal tissue to measure surgical and drug effects on glia-related gene expression.
RESULTS: We observed using the tail flick assay that oliceridine was a 4-fold more potent analgesic than morphine, but that oliceridine treatment caused less tolerance and opioid-induced hyperalgesia than morphine after 4 days of ascending-dose administration. Using similar analgesic doses, morphine caused reward behavior in the conditioned place preference assay while oliceridine did not. Physical dependence was, however, similar for the 2 drugs. Likewise, morphine appeared to more significantly impair the recovery of nociceptive sensitization and gait after tibial fracture and pinning than oliceridine. Furthermore, spinal cord toll-like receptor-4 levels 3 weeks after fracture were higher in fracture mice given morphine than those given oliceridine.
CONCLUSIONS: Aside from reduced respiratory depression, G-protein-biased agonists such as oliceridine may reduce opioid maladaptations and enhance the quality of surgical recovery.

Entities:  

Year:  2019        PMID: 30044299     DOI: 10.1213/ANE.0000000000003662

Source DB:  PubMed          Journal:  Anesth Analg        ISSN: 0003-2999            Impact factor:   5.108


  14 in total

Review 1.  A Biased View of μ-Opioid Receptors?

Authors:  Alexandra E Conibear; Eamonn Kelly
Journal:  Mol Pharmacol       Date:  2019-06-07       Impact factor: 4.436

Review 2.  New sedatives and analgesic drugs for gastrointestinal endoscopic procedures.

Authors:  Jae Min Lee; Yehyun Park; Jin Myung Park; Hong Jun Park; Jun Yong Bae; Seung Young Seo; Jee Hyun Lee; Hyung Ku Chon; Jun-Won Chung; Hyun Ho Choi; Jun Kyu Lee; Byung-Wook Kim
Journal:  Clin Endosc       Date:  2022-08-29

Review 3.  Abuse Potential of Biased Mu Opioid Receptor Agonists.

Authors:  S Stevens Negus; Kevin B Freeman
Journal:  Trends Pharmacol Sci       Date:  2018-11       Impact factor: 14.819

4.  Effectiveness comparisons of G-protein biased and unbiased mu opioid receptor ligands in warm water tail-withdrawal and drug discrimination in male and female rats.

Authors:  Kathryn L Schwienteck; Kaycee E Faunce; Kenner C Rice; Samuel Obeng; Yan Zhang; Bruce E Blough; Travis W Grim; S Stevens Negus; Matthew L Banks
Journal:  Neuropharmacology       Date:  2019-01-18       Impact factor: 5.250

Review 5.  Toward Directing Opioid Receptor Signaling to Refine Opioid Therapeutics.

Authors:  Travis W Grim; Agnes Acevedo-Canabal; Laura M Bohn
Journal:  Biol Psychiatry       Date:  2019-10-31       Impact factor: 13.382

6.  Physiological dependence to mitragynine indicated by a rapid cross-dependence procedure with heroin-dependent mice.

Authors:  Kai Yue; Jonathan L Katz; Xiji Shu
Journal:  Psychopharmacology (Berl)       Date:  2022-02-02       Impact factor: 4.530

7.  Some effects of putative G-protein biased mu-opioid receptor agonists in male rhesus monkeys.

Authors:  Jeremy C Cornelissen; Bruce E Blough; Laura M Bohn; S Stevens Negus; Matthew L Banks
Journal:  Behav Pharmacol       Date:  2021-08-01       Impact factor: 2.277

Review 8.  Biased Opioid Ligands.

Authors:  Abdelfattah Faouzi; Balazs R Varga; Susruta Majumdar
Journal:  Molecules       Date:  2020-09-16       Impact factor: 4.411

Review 9.  Experimental considerations for the assessment of in vivo and in vitro opioid pharmacology.

Authors:  Rob Hill; Meritxell Canals
Journal:  Pharmacol Ther       Date:  2021-07-10       Impact factor: 12.310

Review 10.  Biased versus Partial Agonism in the Search for Safer Opioid Analgesics.

Authors:  Joaquim Azevedo Neto; Anna Costanzini; Roberto De Giorgio; David G Lambert; Chiara Ruzza; Girolamo Calò
Journal:  Molecules       Date:  2020-08-25       Impact factor: 4.411

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.